1286 results for "MDMA"
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Journal of Psychoactive Drugs – October 10, 2025
Summary
One-third of veterans receiving care from Veterans Affairs expressed curiosity about MDMA-assisted therapy (MDMA-AT) for PTSD, highlighting a significant gap in understanding existing treatment options. In a sample of 30 participants, recurring themes included hope and concerns about side effects and addiction potential. Notably, over 10% demonstrated misunderstandings about the therapy and its implications. This insight can guide the creation of targeted psychoeducation materials and standardized surveys to better address veterans' attitudes towards innovative addiction treatments, ultimately enhancing mental health support.
Abstract
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially...
Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour
The International Journal of Neuropsychopharmacology – October 14, 2010
Summary
MDMA significantly enhances dopamine levels in the brain's reward center, the nucleus accumbens, influencing addictive behaviors. In a study with 5-HT2A receptor knockout (KO) mice, self-administration of MDMA was reduced by 40% compared to wild-type (WT) mice at doses of 0.125 and 0.25 mg/kg. Additionally, KO mice exhibited a 30% increase in hyperlocomotion from MDMA (10 and 20 mg/kg) compared to WT. Cue-induced craving for MDMA was effectively blocked with a selective 5-HT2A antagonist at 0.5 mg/kg, highlighting the receptor's critical role in addiction dynamics.
Abstract
The serotonergic system appears crucial for (±)-3,4-methylenedioxymethamphetamine (MDMA) reinforcing properties. Current evidence indicates that se...
Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.
European journal of psychotraumatology – January 01, 2024
Summary
As MDMA-assisted therapy shows promise for treating PTSD, European experts are weighing in on implementation. A survey of 68 international specialists revealed strong support for standardized training and equitable access. They emphasize the need for coordinated regulation across Europe and science-based policy development to ensure safe, effective integration into mental healthcare systems.
Abstract
Introduction: The positive results of MDMA from Phase 2 and 3 clinical trials in MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumati...
A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy
Frontiers in Psychiatry – October 12, 2022
Summary
As many as 40-70% of PTSD patients suffer from refractory disease, highlighting a critical need in psychiatry. MDMA, a powerful psychedelic, shows significant promise in clinical psychology. Its pro-social effects enhance the psychotherapist-patient alliance, facilitating trauma processing. Beyond psychology, a biological mechanism involving increased brain-derived neurotrophic factor (BDNF) in fear memory pathways contributes to its therapeutic action in medicine. This nuanced understanding from psychedelics and drug studies moves beyond simple drug analysis, offering hope for millions.
Abstract
Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe...
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.
European journal of psychotraumatology – January 01, 2024
Summary
No Summary
Abstract
Background: MDMA-assisted psychotherapy (MDMA-AP) is a combined psychotherapeutic and pharmacologic intervention that shows promise in the treatmen...
The Brinzei MDMA-PTSD Protocol: Addressing the Food and Drug Administration’s Breaking Blind Concerns with Precision Approaches to Post-Traumatic Stress Disorder Treatment
Preprints.org – October 03, 2025
Summary
MDMA-assisted therapy (MDMA-AT) significantly alleviates PTSD symptoms, with many patients reporting lasting improvements after treatment. However, regulatory hurdles arise due to challenges in maintaining blinding during trials. A new clinical trial design, the Brinzei MDMA-PTSD Protocol (BMPP), proposes a quadruple-masked approach to minimize bias while delivering effective care. It suggests that acute traumas may resolve in 1-3 sessions, while complex traumas require more structured treatment. This innovative framework aims to clarify the mechanisms of MDMA’s effectiveness and optimize its therapeutic applications.
Abstract
3,4-Methylenedioxyamphetamine (MDMA) has been shown in multiple clinical trials to greatly reduce Post-Traumatic Stress Disorder (PTSD) symptoms, w...
The Conceptual Framework for the Therapeutic Approach used in Phase 3 Trials of MDMA-AT for PTSD
CrossRef
Summary
A new understanding reveals how a successful PTSD therapy harnesses an individual's innate healing intelligence. This framework, now detailed, guides an intensive, short-term approach combining MDMA-facilitated sessions with psychotherapy. It helps patients process trauma and foster self-directed growth within a supportive, non-pathologizing environment. Clinical trials demonstrate significant reductions in PTSD symptoms, with MDMA-assisted treatment outperforming placebo and confirming the strength of this unique therapeutic model.
Abstract
Results from multiple recent studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assi...
MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years.
Current medicinal chemistry – June 02, 2025
Summary
Over three decades of research reveals MDMA-assisted therapy shows remarkable promise in treating PTSD, anxiety, and depression. Analysis of 30 years of scientific literature shows a dramatic shift from studying MDMA's risks to exploring its therapeutic benefits. The U.S. leads research efforts, with breakthrough results demonstrating MDMA's potential to help patients process trauma and emotional distress in controlled therapeutic settings.
Abstract
The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while...
MDMA interactions with pharmaceuticals and drugs of abuse
Expert Opinion on Drug Metabolism & Toxicology – March 31, 2020
Summary
MDMA, widely used as a recreational drug, poses significant risks when combined with other substances. Among users, 60% engage in polydrug use to enhance effects or mitigate toxicity. This practice increases the likelihood of acute MDMA toxicity, particularly when interacting with pharmaceuticals metabolized by the CYP2D6 enzyme. Despite the prevalence of these interactions, only a limited number of studies exist, highlighting an urgent need for more comprehensive investigations into MDMA-drug interactions and their implications for safety and health in recreational settings.
Abstract
Introduction: MDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, has become one of the most widely used recreation...
MDMA and MDMA-Assisted Therapy.
The American journal of psychiatry – January 01, 2025
Summary
MDMA, once known only as a party drug, is showing remarkable promise in clinical drug studies. When combined with therapy, this compound helps 67-71% of PTSD patients achieve remission - more than double the success rate of traditional therapy. Beyond treating PTSD, research suggests MDMA's unique ability to increase trust and self-compassion while maintaining mental clarity makes it valuable for treating depressive disorders. In controlled medical settings, it's proving both safe and effective.
Abstract
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and ther...
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.
Journal of psychiatric research – May 01, 2022
Summary
Many individuals with severe PTSD also struggle with significant eating disorder symptoms, even without a formal diagnosis. Given the lack of integrated treatment, a trial explored if MDMA-Assisted therapy could effectively reduce these co-occurring issues. Adults with severe PTSD were randomized to receive either MDMA-Assisted therapy or placebo. Their eating disorder symptoms were tracked using the EAT-26 questionnaire. Remarkably, those receiving MDMA-Assisted therapy showed a significant reduction in EAT-26 scores, indicating substantial improvement in eating disorder symptoms compared to the placebo group. This positive treatment effect was particularly strong for women with higher baseline scores. The findings highlight MDMA-Assisted therapy as a highly promising treatment for individuals experiencing both PTSD and eating disorders.
Abstract
Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there are no proven integrative treatment modalities for E...
Getting in Touch with Touch: The Importance of Studying Touch in MDMA-Assisted Therapy and the Development of a New Self-Report Measure.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2024
Summary
Touch plays a vital role in MDMA-assisted therapy, yet its effects have rarely been measured systematically. A new assessment tool, the Touch Outcomes Measurement Inventory, helps therapists understand how physical contact impacts clients during psychedelic-assisted therapy sessions. This breakthrough enables better evaluation of touch's therapeutic benefits in MDMA treatment.
Abstract
MDMA-assisted therapy (MDMA-AT) is an emerging treatment modality, with recent phase 3 trials indicating its potential for regulatory approval. Cen...
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
PLoS ONE – February 25, 2022
Summary
MDMA-assisted therapy (MDMA-AT) for severe posttraumatic stress disorder (PTSD) shows remarkable cost-effectiveness, potentially saving $132.9 million over 30 years for 1,000 patients. The recent phase 3 trial involving 90 patients indicated that MDMA-AT costs $11,537 per patient while generating 4,856 quality-adjusted life years (QALYs) and averting 61.4 premature deaths. Notably, adding a third session enhances both medical savings and health benefits. With an incremental cost-effectiveness ratio of $2,384 per QALY gained, MDMA-AT presents a compelling option in psychiatric care.
Abstract
Background Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled e...
Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol
Frontiers in Psychiatry – July 15, 2023
Summary
For those battling severe social anxiety, new hope may emerge from an innovative clinical trial protocol. This psychedelic research investigates MDMA-assisted therapy's potential to significantly reduce social anxiety disorder symptoms. The protocol outlines a study where 20 participants will undergo a structured psychedelic assisted therapy, including MDMA sessions and integration. This pioneering effort aims to establish the feasibility and positive impact of MDMA as a transformative treatment for this debilitating condition.
Abstract
BackgroundSocial anxiety disorder (SAD) is a serious and prevalent psychiatric condition that heavily impacts social functioning and quality of lif...
Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis
Neuropsychopharmacology – April 23, 2024
Summary
MDMA-assisted psychotherapy, a promising approach in Psychology for conditions like Major Depression, involves a psychotherapist and MDMA. A meta-analysis of 8 studies (from 13 identified via searches including MEDLINE) found it increased side effect odds during sessions by 1.67 times and in the following week by 1.59 times compared to controls. Phase 3 Psychedelics and Drug Studies showed 3.51 times higher odds of adverse events. While side effects were mostly mild, reporting quality in these Complementary and Alternative Medicine Studies was poor.
Abstract
Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted ...
Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.
European journal of psychotraumatology – December 01, 2025
Summary
Being kinder to oneself may be key to healing trauma. New findings reveal that MDMA-assisted therapy helps people with posttraumatic stress disorder by boosting self-compassion. In a trial of 82 adults, those receiving MDMA therapy showed major improvements in self-kindness and reduced self-judgment, which directly led to decreased depression and PTSD symptoms.
Abstract
Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcoh...
Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.
Journal of affective disorders – February 02, 2026
Summary
Australia's groundbreaking move to permit prescribed MDMA for PTSD outside trials offers unique insights from those with direct experience. Interviews with 21 Australian clinicians, researchers, and patients underscore the critical need for robust expectation management, comprehensive screening, and ongoing consent. Safeguard measures, a strong therapeutic alliance, and integrated care are also paramount. These perspectives provide invaluable guidance for developing national guidelines as MDMA-assisted psychotherapy integrates into clinical practice.
Abstract
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic ...
Bringing MDMA-assisted therapy for PTSD to traditional healthcare systems: tending to set and setting.
Frontiers in psychiatry – January 01, 2025
Summary
Veterans struggling with PTSD may soon have access to a groundbreaking treatment: MDMA-assisted therapy shows remarkable promise in helping patients process trauma. The Veterans Health Administration is exploring implementation of this psychedelic therapy, which combines MDMA with intensive psychotherapy. Key factors for success include creating optimal therapeutic environments and ensuring proper patient mindset. Early results suggest this approach could transform PTSD treatment for veterans and civilians alike.
Abstract
Although effective evidence-based trauma-focused psychotherapies for posttraumatic stress disorder (PTSD) are available, a significant proportion o...
MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Neuropsychopharmacology reports – December 01, 2024
Summary
A groundbreaking meta-analysis reveals that MDMA-assisted therapy shows remarkable success in treating post-traumatic stress disorder. Analyzing 9 high-quality RCTs with nearly 300 participants, researchers found that MDMA-AT significantly reduced PTSD symptoms and doubled remission rates compared to placebo treatments. The therapy proved both safe and effective, with no increase in adverse effects.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating ...
MDMA-Assisted Psychotherapy for Borderline Personality Disorder.
Focus (American Psychiatric Publishing) – October 01, 2022
Summary
Groundbreaking research reveals MDMA-assisted psychotherapy shows promise for treating borderline personality disorder, a condition that traditionally responds inconsistently to standard treatments. The therapeutic combination of MDMA with professional counseling may help patients process trauma, regulate emotions, and build trust more effectively than conventional approaches. Early clinical trials demonstrate encouraging safety profiles and symptom improvements, particularly in areas of emotional regulation and interpersonal relationships.
Abstract
Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in tr...
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder.
Frontiers in psychiatry – January 01, 2022
Summary
Brain imaging reveals how MDMA-assisted therapy can help heal trauma. Using fMRI, researchers observed positive shifts in brain activity and functional connectivity in individuals with PTSD after MDMA therapy. A beneficial trend emerged in amygdala-hippocampus resting-state connectivity, alongside reduced brain response to trauma. Importantly, recovery from PTSD correlated with improved functional connections, including between the amygdala, hippocampus, and insula, particularly during autobiographical memory recall. These findings suggest MDMA positively impacts brain networks crucial for emotional processing and memory.
Abstract
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinica...
Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”
Frontiers in Psychiatry – October 26, 2022
Summary
New hope emerges for Major depressive disorder, a debilitating brain disorder. A clinical trial is investigating MDMA-assisted therapy as a potential new medicine. Twelve participants will undergo MDMA dosing over two sessions, integrated with psychological support. This open-label trial in psychiatry assesses safety, including potential adverse effects, and gathers initial insights into effectiveness, aiming to inform future assessments of overall clinical impression. This work contributes to the growing field of psychedelics and drug studies.
Abstract
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and ...
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder
medRxiv Preprint Server – May 25, 2022
Summary
Brain imaging shows how 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) may reshape neural pathways in post-traumatic stress disorder (PTSD). Researchers explored if MDMA-AT alters brain activity and connections in regions like the amygdala and hippocampus. Using fMRI, they scanned veterans and first responders with chronic PTSD before and after therapy. While a direct increase in amygdala-hippocampus resting connectivity was a trend, significant positive changes were found. Recovery from PTSD correlated with improved functional connections involving the amygdala and insula, suggesting a beneficial shift in how the brain processes traumatic memories and regulates the fear response. This highlights MDMA-AT's positive impact on key brain areas for PTSD.
Abstract
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinica...
MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.
CNS spectrums – January 30, 2025
Summary
MDMA-assisted therapy shows remarkable promise, with 67% of PTSD patients no longer meeting diagnostic criteria after treatment. This novel therapeutic innovation combines psychotherapy with carefully administered MDMA in clinical settings. FDA breakthrough status has accelerated research, as mounting evidence shows effectiveness for behavioral disorders and mental health conditions. Current drug regulations are evolving to accommodate this psychedelic research renaissance.
Abstract
This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and ...
Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.
Social work – April 01, 2025
Summary
While MDMA shows promise for treating PTSD in adults, social workers express greater confidence in traditional medications for adolescent patients. A survey of 222 social workers revealed they favored selective serotonin reuptake inhibitors over MDMA therapy for treating teen PTSD. However, those with more knowledge about psychedelics showed less stigma and concern, suggesting education could increase acceptance of this emerging treatment.
Abstract
Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adoles...
Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
Journal of Psychopharmacology – April 26, 2016
Summary
MDMA-assisted psychotherapy (MDMA-AP) shows significant promise for treating posttraumatic stress disorder (PTSD), outperforming prolonged exposure (PE) therapy. In a meta-analysis comparing clinical trials, MDMA-AP demonstrated larger effect sizes: 1.17 for clinician-observed outcomes versus 1.08 for PE, and 0.87 versus 0.77 for patient self-reports. Additionally, MDMA-AP had a notably lower dropout rate, indicating better tolerability among patients. With these findings, MDMA-AP emerges as a compelling alternative in the treatment landscape for PTSD, alongside traditional therapies like exposure therapy.
Abstract
Since the wars in Iraq and Afghanistan, posttraumatic stress disorder (PTSD) has become a major area of research and development. The most widely a...
MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review.
PloS one – January 01, 2025
Summary
Many with chronic post-traumatic stress disorder (PTSD) achieved a loss of diagnosis (LOD) with 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT). A review compared MDMA-AT to current treatments for severe, resistant PTSD, using the Clinician-Administered PTSD Scale (CAPS) and Beck Depression Inventory (BDI). MDMA-AT consistently showed significantly greater, durable improvements in CAPS and BDI, and high LOD rates, outperforming most standard options. This highlights MDMA-AT's strong, consistent positive results.
Abstract
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is currently being evaluated for treatment of patients with moderate or higher severit...
MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.
CNS drugs – April 01, 2025
Summary
MDMA-assisted therapy shows remarkable promise in treating PTSD, with nearly 70% of participants experiencing such significant improvement that they no longer met diagnostic criteria. This breakthrough approach combines psychotherapy with carefully administered MDMA doses, creating a therapeutic window where patients can process trauma more effectively. Despite positive clinical results, regulatory hurdles remain due to concerns about trial design and safety protocols.
Abstract
Trauma is prevalent, with lifetime estimates of traumatic exposure ranging from 70% for a single event to 31% for multiple events. While many recov...
Late diagnosis of MDMA-related severe hyponatremia
Case Reports in Internal Medicine – May 27, 2014
Summary
A 24-year-old woman experienced a severe hyponatremic coma, with serum sodium dropping to a critical 116 mmol/L and significant brain edema. Initial assessments failed to identify MDMA use, as her family denied any illicit drug consumption. It wasn't until six days later that toxicology revealed an alarming MDMA concentration of 7,767 ng/ml in her urine. This case highlights the challenge of diagnosing MDMA-induced hyponatremia without a clear drug history and emphasizes the necessity for prompt toxicological screening in similar situations.
Abstract
Introduction : 3, 4-methylenedioxymethamphetamine (MDMA) is a popular psychoactive amphetamine derivative with the potential to induce life-threate...
Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder
Open Science Framework – January 01, 2026
Summary
Individuals undergoing MDMA-assisted therapy for social anxiety disorder may experience significant increases in self-compassion, which could enhance mental health outcomes. With a focus on 100 participants, the study aims to track changes in trait self-compassion throughout treatment and assess how state self-compassion during dosing sessions influences these changes. Key areas of evaluation include reductions in social anxiety symptoms, depressive symptoms, and internalized shame. The findings could illuminate the biological mechanisms behind improved wellbeing and functional outcomes in clinical psychology.
Abstract
Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorde...
MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials
Journal of Psychoactive Drugs – November 05, 2025
Summary
MDMA-assisted psychotherapy (MDMA-AT) shows significant promise for treating posttraumatic stress disorder (PTSD). In a systematic review of seven randomized controlled trials involving 280 adults, 83.3% of studies reported notable reductions in PTSD symptoms for those receiving MDMA compared to placebo. Remarkably, 41.7% to 85.7% of participants treated with MDMA no longer met PTSD criteria after therapy, versus 25.0% to 33.3% in placebo groups. This evidence highlights MDMA-AT's potential as a viable mental health treatment, though further ethical research is essential for FDA approval.
Abstract
Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxym...
Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder
Journal of Humanistic Psychology – June 23, 2021
Summary
Remarkably, individuals with severe PTSD experienced significant symptom reduction through a novel therapy. This research explored whether a structured MDMA-assisted therapy could be effectively delivered across multiple clinics. Trained therapy teams provided three sessions to participants, with the treatment consistently delivered across 14 North American sites. Findings revealed substantial decreases in PTSD symptom severity, and the therapy was well-tolerated. These positive results demonstrate this approach can achieve meaningful improvements and be successfully scaled for wider access.
Abstract
Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and func...
[MDMA-assisted therapy for PTSD].
Laeknabladid – May 01, 2024
Summary
MDMA, known for its unique empathogen properties, shows remarkable promise in treating severe PTSD. When combined with psychotherapy, this psychedelic medicine helps patients process trauma with reduced fear and anxiety. Clinical sessions pair the substance with 8-hour therapeutic support, allowing patients to explore difficult memories while feeling safe and supported. Results show significant symptom reduction and high treatment success rates.
Abstract
MDMA is a potential novel treatment for post-traumatic stress disorder (PTSD). Our goal is to review current knowledge on MDMA and its use in MDMA-...
MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.
European child & adolescent psychiatry – November 01, 2024
Summary
No Summary
Abstract
3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may b...
Tags
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Nature medicine – October 01, 2023
Summary
No Summary
Abstract
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assist...
Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.
Contemporary clinical trials communications – October 01, 2024
Summary
Veterans battling both PTSD and alcohol use disorder may find hope in a groundbreaking therapy approach. This pioneering trial explores MDMA-assisted psychotherapy as a dual treatment, combining supervised MDMA sessions with therapeutic support. The study follows 12 veterans through comprehensive treatment, tracking brain changes and measuring improvements in both trauma symptoms and alcohol use. Early indicators suggest this innovative approach could offer relief where traditional treatments have fallen short.
Abstract
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than eithe...
Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats
Social Neuroscience – June 21, 2008
Summary
MDMA, commonly known as "Ecstasy," significantly enhances social behavior in male Wistar rats. In a study involving 80 rats, those treated with 5 mg/kg of MDMA and allowed social interaction displayed markedly increased social engagement compared to their untreated counterparts, showing heightened investigation behaviors. Notably, 30 brain regions exhibited increased neural activation in MDMA-treated groups, particularly in areas like the nucleus accumbens and medial amygdala. These findings suggest that MDMA amplifies specific neural circuits associated with prosocial behavior, possibly influenced by oxytocin.
Abstract
The popular drug 3,4 methylenedioxymethamphetamine (MDMA, "Ecstasy", "the Love Drug") produces feelings of love and closeness in humans and induces...
The case for an integrative model: Hypotheses and rationale for integrative MDMA-Assisted Psychotherapy (IMAP)
Psychedelics – January 08, 2026
Summary
Integrative MDMA-Assisted Psychotherapy (IMAP) offers a promising model for PTSD treatment, emphasizing flexibility and a patient-driven approach. Unlike traditional therapy, which often relies on rigid protocols, IMAP supports the nonlinear healing processes that characterize MDMA-assisted therapy. This model incorporates contemporary PTSD theories and evidence-based trauma interventions, ensuring a grounded foundation while retaining the experiential ethos of humanistic psychology. By inviting empirical investigation into essential therapeutic elements, IMAP aims to enhance the effectiveness of psychedelic therapies, potentially benefiting a broader range of patients.
Abstract
The original MAPS manual for MDMA-assisted therapy (MDMA-AT) opened a therapeutic frontier for PTSD. However, it drew critique for concepts—such as...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
The British journal of psychiatry : the journal of mental science – July 11, 2025
Summary
A new approach to treating severe depression shows significant promise. In recent clinical drug studies, a novel medication-assisted treatment involving MDMA alongside psychotherapy was explored for Major Depressive Disorder. Twelve participants with moderate to severe depression received two MDMA sessions, integrated with comprehensive psychotherapy. Results were highly positive: participants experienced significant reductions in depression symptoms and improved daily functioning, with no serious side effects. This innovative medication-assisted treatment demonstrated safety and strong indications of efficacy.
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic st...
Studies of MDMA-Induced Neurotoxicity in Nonhuman Primates: A Basis for Evaluating Long-Term Effects in Humans
PsycEXTRA Dataset – January 01, 1989
Summary
MDMA exhibits significant neurotoxic effects in primates, with monkeys showing heightened sensitivity compared to rats. At a toxic dose of 5 mg/kg, close to the typical human dosage of 1.7 to 2.7 mg/kg, MDMA impacts both serotonergic nerve fibers and cell bodies in monkeys. This steep dose-response curve indicates a narrow margin of safety, raising concerns about potential neurotoxicity in humans. Additionally, cerebrospinal fluid levels of 5-HIAA may serve as a biomarker for MDMA-induced serotonergic damage in the primate central nervous system.
Abstract
The results of the studies reviewed here show that the neurotoxic effects of MDMA generalize to the primate. Further, they indicate that monkeys ar...
Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach.
Frontiers in psychiatry – January 01, 2025
Summary
MDMA's unique ability to enhance empathy and trust may offer breakthrough treatment for pathological narcissism. This novel approach combines psychedelic medicine with psychoanalytic therapy to address deep-rooted personality patterns. By reducing fear responses and promoting emotional openness, MDMA-assisted therapy helps process early trauma and strengthen self-awareness, potentially transforming treatment-resistant narcissistic traits.
Abstract
Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity a...
Time-Dependent Molecular Changes Following MDMA-Induced Nephrotoxicity.
Iranian journal of pharmaceutical research : IJPR – January 01, 2024
Summary
The party drug ecstasy (3,4-Methylenedioxymethamphetamine) can cause acute kidney injury through complex molecular changes. New findings reveal that a single dose temporarily disrupts kidney function by altering inflammatory signals and cell death pathways. While no permanent tissue damage occurred, the drug reduced key protective proteins that help regulate inflammation and prevent cell death through apoptosis.
Abstract
The increasing recreational use of ecstasy (MDMA) poses significant risks to human health, including reports of fatal renal failure due to its adve...
Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model.
PloS one – January 01, 2024
Summary
MDMA-assisted therapy could save the US healthcare system money while significantly improving outcomes for PTSD patients. This groundbreaking analysis reveals that despite higher upfront costs, MDMA therapy proves cost-effective by reducing long-term healthcare visits and additional treatments. Patients receiving MDMA therapy showed better quality of life outcomes compared to traditional therapy alone, with benefits lasting over a 5-year period.
Abstract
To explore the cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) compared to placebo with therapy (PT) in US healthcare settings. A h...
Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology – June 27, 2010
Summary
MDMA, commonly known as ecstasy, is linked to significant organ damage, primarily through increased oxidative stress. In a review of studies involving MDMA-exposed rats, researchers identified 115 oxidatively-modified mitochondrial proteins, highlighting how these modifications lead to mitochondrial dysfunction. This work utilized a novel proteomics method to track protein changes, offering insights into the harmful interactions between MDMA and other substances like alcohol. These findings pave the way for developing preventive and therapeutic strategies against the organ damage caused by MDMA.
Abstract
Despite numerous reports about the acute and sub-chronic toxicities caused by MDMA (3,4-methylenedioxymethamphetamine, ecstasy), the underlying mec...
Zinc Mitigates MDMA-Prompted Apoptosis by Alteration of Cross Talk Among Bcl-2, Bax and P53 Genes Expression in Mouse Sertoli and Leydig Cell Lines.
Reports of biochemistry & molecular biology – October 01, 2024
Summary
New research reveals that zinc supplementation may protect male reproductive cells from damage caused by Ecstasy (MDMA). Scientists found that zinc helps prevent cell death (apoptosis) in critical testicular cells - Sertoli and Leydig cell lines. By regulating key genetic signals, zinc appears to shield these reproductive cells from MDMA's harmful effects, suggesting potential protective benefits.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) affects the male reproductive system. We investigated the mRNA levels of bax, bcl-2, and p53 genes in MDMA...
Is there a case for MDMA-assisted psychotherapy in the UK?
Journal of Psychopharmacology – February 28, 2007
Summary
MDMA, often viewed through the lens of recreational risks, has a compelling history as an effective therapeutic tool in psychotherapy. Recent interest is rekindled, with multiple double-blind randomized controlled trials underway to explore its potential benefits. The author emphasizes the importance of cautious yet open-minded discussions within the medical community regarding MDMA's role in modern psychiatric practice. By understanding both its historical context and recent scientific inquiries, there’s potential for MDMA to serve as a valuable adjunct in treatment, benefiting patients seeking psychological healing.
Abstract
Much has been written in scientific and popular literature in recent years about the dangers surrounding the recreational use of the drug MDMA/ecst...
MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial.
European journal of psychotraumatology – December 07, 2020
Summary
A new **treatment** approach offers a promising insight: healing individual trauma can also strengthen relationships. An initial test explored **MDMA**-facilitated **cognitive-behavioural conjoint therapy** for **PTSD**. Six **couple**s, one partner with **PTSD**, underwent condensed **therapy** with two **MDMA** sessions. All completed safely. Significant improvements were seen in **PTSD** symptoms for both patients and partners, plus better depression, sleep, and emotion regulation. Relationship adjustment and happiness also improved, suggesting this **conjoint** method robustly enhances individual and relational well-being.
Abstract
Cognitive-behavioural conjoint therapy (CBCT) for PTSD has been shown to improve PTSD, relationship adjustment, and the health and well-being of pa...
5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA.
bioRxiv : the preprint server for biology – October 22, 2024
Summary
MDMA's unique effect on brain chemistry makes it less addictive than similar drugs while maintaining therapeutic benefits. New research reveals how serotonin release in a key reward center of the brain acts as a natural brake on MDMA's addictive properties, while preserving its positive social effects. This explains why MDMA shows promise in therapy without the high abuse risk of similar substances.
Abstract
MDMA is a promising adjunct to psychotherapy and has well-known abuse liability, although less than other amphetamine analogs. While the reinforcin...
3,4-methylenedioxymethamphetamine (MDMA): current perspectives
Substance Abuse and Rehabilitation – November 01, 2013
Summary
MDMA (Ecstasy) shows promise in Medicine, with initial Psychology and Pharmacology findings indicating effective treatment for chronic PTSD. While a potent euphoriant influencing Serotonin and other neurotransmitter receptors, recreational amphetamine use can cause adverse effects like mood lowering for 2-5 days. Neuroscience reveals long-term Serotonergic changes in animal models and altered Serotonin transporter binding in heavy users. These Psychedelics and Drug Studies highlight MDMA's complex profile, from therapeutic agent to risky substance, demanding careful Forensic Toxicology analysis.
Abstract
Ecstasy is a widely used recreational drug that usually consists primarily of 3,4-methylenedioxymethamphetamine (MDMA). Most ecstasy users consume ...
MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology
Current Neuropharmacology – August 01, 2013
Summary
MDMA, or Ecstasy, is unique among psychotropic substances for inducing an "open mind state," which offers potential therapeutic benefits in treating neuropsychiatric disorders. Despite its promise, only a few MDMA analogues have been studied, with limited evidence supporting their effectiveness in replicating MDMA's complex pharmacological profile. This review highlights the need for further exploration of MDMA's structure-activity relationships and the potential development of new analogues to enhance its therapeutic applications in psychology and medicine, addressing treatment failures in existing therapies.
Abstract
Besides stimulants and hallucinogens, whose psychotropic effects are shared by many structurally related molecules exhibiting different efficacies ...
History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
British Journal of Pharmacology – October 21, 2025
Summary
MDMA-assisted psychotherapy has shown significant promise in treating posttraumatic stress disorder (PTSD), with studies indicating an efficacy rate of over 60% in symptom reduction. This review examines MDMA's journey from military interrogation to clinical use, highlighting its effects on prosocial behavior, reduced threat perception, and euphoria. Central to its therapeutic potential is serotonin's role in mediating these effects. With a focus on addressing existing gaps in understanding MDMA’s mechanisms, the findings aim to enhance future clinical practices and develop safer therapeutic agents.
Abstract
The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic st...
Behavioral Psychopharmacology of MDMA and MDMA-Like Drugs: A Review of Human and Animal Studies
Addiction Research & Theory – January 01, 2002
Summary
MDMA, commonly known as ecstasy, exhibits unique behavioral effects in both humans and animals, revealing its potential therapeutic value despite concerns over neurotoxicity. In studies involving over 1,000 participants, MDMA demonstrated significant influence on locomotor activity and startle response, with notable alterations in behavior linked to its serotonergic properties. The ongoing examination of MDMA and similar drugs is crucial for understanding their impact on cognition, arousal, and motor functions, while also addressing issues related to recreational use and drug safety.
Abstract
Since being classified as a Schedule I controlled substance, MDMA (3,4-methylenedioxy-N-methylamphetamine; "ecstasy") has been the subject of contr...
Couple Therapy With MDMA-Proposed Pathways of Action.
Front Psychol – November 11, 2021
Summary
Exploring how MDMA could enhance couple therapy reveals promising pathways for relationship healing. This theoretical framework proposes that MDMA, when integrated with therapy, can significantly deepen emotional connection and communication. It suggests mechanisms like reduced fear and heightened empathy, fostering stronger bonding and leading to more positive therapeutic outcomes for couples seeking profound connection.
Abstract
Couple Therapy With MDMA-Proposed Pathways of Action.
Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment
Neuropsychopharmacology – May 11, 2011
Summary
MDMA significantly impairs memory, particularly verbal memory, as shown by a study involving 17 participants. Performance on a word-learning task dropped notably with MDMA use, while pretreatment with a 5-HT(2A) receptor blocker, ketanserin, protected against this impairment. Specifically, ketanserin prevented memory deficits in the word-learning task but not in spatial or prospective memory tasks. In contrast, a 5-HT(1A) receptor blocker, pindolol, showed no protective effect. These findings highlight the crucial role of neurotransmitter receptors in MDMA-induced memory impairment, offering insights for forensic toxicology and drug analysis.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) or 'ecstasy' has been associated with memory deficits during abstinence and intoxication. The human neurop...
Effects of MDMA-assisted therapy for PTSD on self-experience
PLoS ONE – January 10, 2024
Summary
MDMA-assisted therapy dramatically improved self-experience and emotional coping for 90 participants in a randomized controlled trial. Compared to placebo, those receiving MDMA therapy showed significant gains in self-compassion and reduced alexithymia, crucial for processing trauma. This clinical psychology finding, involving 46 MDMA recipients versus 44 placebo, suggests MDMA's potential in psychiatry and medicine to enhance psychotherapy techniques, especially for individuals with complex trauma (84.4% had developmental trauma), by improving affect regulation and reducing psychosomatic distress.
Abstract
Introduction There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MD...
The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.
Psychiatry research – September 01, 2024
Summary
MDMA, when combined with therapy, shows remarkable promise in treating Posttraumatic Stress Disorder (PTSD). A comprehensive meta-analysis of seven clinical trials found that this treatment significantly reduced PTSD symptoms compared to placebo groups. While some patients experienced mild side effects like muscle tension, the benefits of 3,4-Methylenedioxymethamphetamine therapy outweighed risks in controlled settings.
Abstract
3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psy...
The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD.
Frontiers in psychology – January 01, 2024
Summary
MDMA-assisted therapy shows remarkable promise for treating post-traumatic stress disorder by combining psychedelic medicine with trauma-informed care. This approach uniquely emphasizes the patient's inner healing intelligence, allowing them to guide their own recovery while therapists provide support. The treatment pairs traditional psychotherapy with three MDMA sessions, creating a non-pathologizing environment where patients safely process trauma and achieve lasting healing.
Abstract
Results from multiple recent studies support further evaluation of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e....
MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
Frontiers in Psychiatry – October 10, 2022
Summary
Transgender people face significant barriers in trauma-related mental health care, underscoring the need for inclusive approaches in medicine. A focus group study with 17 Transgender participants revealed frustrations with psychotherapists lacking cultural humility. For MDMA-assisted psychotherapy, vital for clinical psychology and psychiatry, recommendations include gender-affirming care, culturally safe settings, and diverse co-therapy teams. This ensures equitable inclusion for this population, informing future drug studies and psychotherapy techniques to address mental illness and improve mental health.
Abstract
Introduction Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at hi...
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Psychopharmacology – September 01, 2019
Summary
Remarkably, over half of individuals receiving MDMA-assisted psychotherapy for Posttraumatic stress disorder no longer met diagnostic criteria. This pooled analysis of six trials investigated a novel approach using the psychedelic MDMA alongside therapy. Participants with PTSD received active MDMA or a control during structured psychotherapy sessions. Results showed significant reductions in PTSD symptoms and related anxiety, with MDMA-assisted psychotherapy proving highly effective and well-tolerated. This promising treatment is advancing.
Abstract
Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment o...
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.
Journal of psychopharmacology (Oxford, England) – August 01, 2017
Summary
Healing from severe trauma could fundamentally reshape one's personality, a recent investigation suggests. This research explored if increased openness and decreased neuroticism drive the positive treatment outcome in MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Using the NEO personality inventory in a randomized trial, it was found that enhanced openness significantly contributed to reduced PTSD symptoms after MDMA pharmacotherapy. Both increased openness and decreased neuroticism were observed long-term, indicating this psychotherapy can lead to lasting, positive personality changes beyond symptom relief. This highlights a powerful mechanism for enduring recovery.
Abstract
A growing body of research suggests that traumatic events lead to persisting personality change characterized by increased neuroticism. Relevantly,...